New Jersey Assembly Bill A1811

New Jersey 2022-2023 Regular Session

• Introduced: 1/11/22
• Refer: 1/11/22

Caption

Requires continued coverage of prescription drugs for certain medical conditions.

Impact

The bill introduces significant changes to how health insurance policies handle appeals regarding prescription drug coverage. Specifically, it precludes insurers from setting limits on maximum coverage for the drugs in question, increasing out-of-pocket costs for covered individuals, or reclassifying medications to more restrictive tiers during the appeals process. The implications of this legislation are especially pertinent given that those affected often depend on these medications for serious health conditions, potentially preventing treatment interruptions that could exacerbate their situations.

Summary

Assembly Bill A1811, which is currently introduced in the New Jersey Legislature, aims to ensure the continued coverage of prescription drugs for individuals diagnosed with complex or chronic medical conditions or rare diseases during the appeals process for coverage denial based on medical necessity. The bill is designed to protect vulnerable patients from losing access to necessary medications while they are appealing decisions made by health insurance providers. It specifies that health insurance carriers must maintain coverage if the drug was previously covered under the policy, regardless of the appeal's status.

Contention

While the intention behind A1811 is largely viewed as positive with respect to protecting patients, there may be dissenting opinions from insurance companies concerned about the financial implications of such requirements. Insurers might argue that the mandate places undue burdens on them to maintain coverage during appeals, which could lead to increased premium costs for all policyholders. Thus, the bill may face opposition primarily focusing on the economic impact versus the ethical considerations of ensuring patient access to critical medications.